HLS Therapeutics (TSX:HLS) LT-Debt-to-Total-Asset: 0.30 (As of Mar. 2026)

What is HLS Therapeutics LT-Debt-to-Total-Asset?

HLS Therapeutics TSX:HLS +2.90% 62 LT-Debt-to-Total-Asset is 0.30 as of Mar. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.47 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HLS Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.30.

HLS Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.38) to Mar. 2026 (0.30). It may suggest that HLS Therapeutics is progressively becoming less dependent on debt to grow their business.

HLS Therapeutics (TSX:HLS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

HLS Therapeutics LT-Debt-to-Total-Asset Related Terms

HLS Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics LT-Debt-to-Total-Asset Chart

HLS Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.35

0.39

0.38

0.33

HLS Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.38	0.33	0.35	0.33	0.30

62GF Score

HLS Therapeutics Inc TSX:HLS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

HLS Therapeutics LT-Debt-to-Total-Asset Calculation

HLS Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	62.084	/	189.721
	=	0.33

HLS Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	53.8	/	179.851
	=	0.30

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.30 mean?

HLS Therapeutics (TSX:HLS) has a LT-Debt-to-Total-Asset of 0.30 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on HLS Therapeutics and its competitors.

Is HLS Therapeutics' LT-Debt-to-Total-Asset too high?

HLS Therapeutics' current LT-Debt-to-Total-Asset is 0.30. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does HLS Therapeutics' LT-Debt-to-Total-Asset compare to ZTS and UTHR?

HLS Therapeutics' LT-Debt-to-Total-Asset of 0.30 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current LT-Debt-to-Total-Asset is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is HLS Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.26 — trading 4.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.30. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current LT-Debt-to-Total-Asset is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.26 is trading 4.7% below its estimated GF Value™ of C$4.47. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

LT-Debt-to-Total-Asset: 0.30
GF Value™: C$4.47 vs. price of C$4.26 (4.7% below fair value)
GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSX:MDP XCNQ:JUSH TSX:CWEB XCNQ:AAWH.U XCNQ:GRIN XCNQ:NVRS TSXV:RX TSX:LOVE TSX:CRDL TSXV:DB XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges HLTRF:USA 74D:Germany

Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2

Website https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.

62GF Score

Get the complete analysis for TSX:HLS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.26

Price

C$4.47

GF Value

View TSX:HLS Analysis

See LT-Debt-to-Total-Asset data for all stocks →